|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvalYear
|
1970s
|
|
gptkbp:approvedBy
|
gptkb:Italy
|
|
gptkbp:ATCCode
|
N06AX05
|
|
gptkbp:availableGeneric
|
yes
|
|
gptkbp:brand
|
gptkb:Desyrel
gptkb:Oleptro
gptkb:Trittico
|
|
gptkbp:CASNumber
|
19794-93-5
|
|
gptkbp:chemical_compound
|
C19H22ClN5O
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
hypersensitivity to trazodone
|
|
gptkbp:developedBy
|
gptkb:Angelini
|
|
gptkbp:drugClass
|
serotonin antagonist and reuptake inhibitor
triazolopyridine
|
|
gptkbp:eliminationHalfLife
|
5-13 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:FDAApproved
|
yes
|
|
gptkbp:form
|
gptkb:tablet
extended-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trazodone
|
|
gptkbp:interactsWith
|
gptkb:beer
CYP3A4 inhibitors
other CNS depressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
serotonin antagonist and reuptake inhibitor
|
|
gptkbp:meltingPoint
|
86-87°C
|
|
gptkbp:metabolism
|
gptkb:m-chlorophenylpiperazine_(mCPP)
liver
|
|
gptkbp:overdoseSymptoms
|
gptkb:arrhythmia
seizures
respiratory depression
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
89-95%
|
|
gptkbp:PubChem_CID
|
5533
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
nausea
dizziness
drowsiness
dry mouth
priapism
|
|
gptkbp:UNII
|
4A0TQ1F604
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
insomnia
anxiety disorders
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|